Nobivac® Feline 1-HCPCh+FeLV

Feline 1-HCPCh+FeLV

A quality core vaccine shown to be effective against multiple viruses, as well as feline Chlamydophila felis* and feline leukemia.

Product Description

FELINE 1-HCPCh+FeLV provides feline protection

Nobivac^® Feline 1-HCPCh+FeLV vaccine is a combination vaccine that unites the benefits of Nobivac^® Feline 1-HCPCh and Nobivac^® 2-FeLV in one vaccination.

A quality core vaccine shown to be effective for vaccination of healthy cats 9 weeks of age or older against feline rhinotracheitis, calici, panleukopenia, and feline leukemia viruses, as well as feline Chlamydophila. The duration of immunity against feline leukemia virus is at least 2 years.
Nobivac^® Feline 1-HCP has been shown to block the replication of canine parvovirus (CPV) in cats¹
- Evidence shows that CPV-2a, CPV-2b, and CPV-2c isolates can replicate in cats, producing clinical signs of feline panleukopenia^61-63
Only Nobivac® FeLV vaccines are labeled to be effective against persistent viremia in cats exposed to virulent leukemia virus.ss^{1, 64}
Superior Efficacy demonstrated vs. multiple FeLV vaccines^{65, 66}
- Nobivac® FeLV vaccines are the ONLY USDA-licensed vaccines that offer 2-Year Duration of Immunity (DOI) (Ideal for adherence to AAFP guidelines).ss^{1, 64, 67}
Goes beyond effectiveness against core antigens and also has been shown to be effective against FeLV and Chlamydophila felis* infection.
The optimal choice for indoor and outdoor cats and cats that are boarded frequently

product Label

Overview

Safety

Administration

Alternate

Disease Information

Indications:

Shown to be effective for vaccination of healthy cats 9 weeks of age or older against feline rhinotracheitis, calici, panleukopenia, and feline leukemia viruses, as well as feline Chlamydophila.

The duration of immunity against feline leukemia virus is at least 2 years.

Also shown to be effective against persistent viremia in cats exposed to virulent feline leukemia virus.
(Previously knowns as Chlamydia psittaci)

FELINE 1-HCPCH+FELV IS A SAFE CHOICE

Proven safety profile-99% reaction-free in ongoing surveillance involving millions of doses.¹

ADMINISTRATION AND DOSAGE

Subcutaneous or intramuscular injection
Initial 1 mL dose administered at 9 weeks of age or older
Second 1 mL dose administered 3 to 4 weeks later
Historically, annual revaccination has been recommended for this product. The need for this booster has not been established. For more information on revaccination frequency, in general or in the face of maternal antibody, consult your veterinarian or the manufacturer.
Available in a 25 x 1 mL dose presentation